• Explore /
  • Poster
  • / First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset.

First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset.

Abstract Poster

Authors

null

Guru Sonpavde

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL

Guru Sonpavde , Ahong Huang , Li Wang , Onur Baser , Raymond Miao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 156)

DOI

10.1200/JCO.2017.35.6_suppl.156

Abstract #

156

Poster Bd #

F10

Abstract Disclosures

Similar Posters

First Author: William K. Oh

First Author: Emily Nash Smyth

First Author: Mehmet Asim Bilen

First Author: Mehmet Asim Bilen